Discover investment opportunities in Small Cap Cancer Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Small Cap Cancer Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Small Cap Cancer Stocks using our Smart AI Filter.
5 stocks found for "Small Cap Cancer Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.19 | ±71.0% | -1.1 | 0.00% | |||
0.90 | ±67.1% | -2.1 | 0.00% | |||
0.48 | ±46.1% | -0.7 | 0.00% | |||
1.38 | ±66.6% | 36.6 | 0.00% | |||
1.20 | ±91.7% | -3.2 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 130.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read moreBicycle Therapeutics (BCYC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read moreImmunic Inc (NASDAQ: IMUX) has executed an in-license agreement with the University Medical Center Goettingen covering the combination of DHODH inhibitors and nucleoside analogs to treat viral infections (COVID-19 and Influenza). The terms of the agreement were not disclosed.
Read moreQ: What are some key growth prospects for small-cap cancer stocks like AVEO and MACK?
A: Small-cap cancer stocks such as AVEO and MACK often focus on niche therapies and innovative treatments. These companies may unlock significant growth through successful clinical trials, FDA approvals, and strategic partnerships. However, their volatile nature requires careful analysis.
Q: Do small-cap cancer stocks like CYRX and CGEN generally offer dividend income to investors?
A: Small-cap cancer stocks like CYRX and CGEN typically do not offer dividends as they reinvest earnings into research and development to drive future growth. Investors may focus more on capital appreciation potential.
Q: How do regulatory factors impact small-cap cancer stocks such as CRIS and INFI?
A: Regulatory factors can significantly impact small-cap cancer stocks like CRIS and INFI. Delays or denials in clinical trial approvals can affect share prices and investor sentiment. Conversely, positive regulatory news can lead to price surges.
Q: What makes CLGN a potentially attractive investment in the small-cap cancer sector?
A: CLGN's attraction may lie in its innovative research pipeline and potential breakthroughs in cancer treatments. Successes could lead to partnerships with larger firms, although risks remain due to the costs and uncertainties of clinical trials.
Q: How have small-cap cancer stocks like CALA performed during market downturns historically?
A: Historically, small-cap cancer stocks such as CALA can exhibit high volatility during market downturns, often reflecting broader investor risk aversion. Their small size and specific business focus can lead to larger price swings compared to larger pharmaceuticals.
Q: Are there specific ESG considerations for investing in small-cap cancer stocks like SLS?
A: ESG considerations in small-cap cancer stocks like SLS may include ethical drug development practices, environmental impacts of manufacturing processes, and corporate governance. Investors may seek transparency and sustainability in business operations.